November 2012, Vol 1, No 5

Frontline Therapy of Metastatic Renal Cell Carcinoma: Pazopanib as Effective as Sunitinib

According to a phase 3 noninferiority trial, paz­opanib is similarly effective as sunitinib, with some advantages in its side effect profile. The COMPARZ trial, reported at the 2012 ESMO Congress, met its primary end point by demonstrating that paz­opanib was noninferior to sunitinib, a standard frontline therapy in this setting. [ Read More ]

Phoebe Starr

2012 ESMO Congress

Crizotinib Extends Survival Versus Chemotherapy in Advanced NSCLC

The PROFILE 1007 trial, reported at the 2012 ESMO Congress, showed positive results for a targeted therapy in patients whose tumors expressed that target. The first-in-class ALK inhibitor crizotinib prolonged progression-free survival (PFS) and improved response rates compared with single-agent chemotherapy in patients with advanced, previously treated, ALK-positive (ALK+), non–small [ Read More ]

Phoebe Starr

2012 ESMO Congress

EGFR Mutations, Not KRAS Mutations, May Be Predictive for Sorafenib Response in Advanced NSCLC

Treatment with sorafenib did not improve overall survival (OS) in patients with heavily pretreated advanced non–small cell lung cancer (NSCLC) in the overall analysis of the MISSION trial reported at the 2012 ESMO Congress. A post hoc companion biomarker study of MISSION presented at the same meeting suggested that EGFR [ Read More ]

Phoebe Starr

2012 ESMO Congress

Whole Genome Testing Moves Forward in Breast Cancer

Researchers presented the first large study to test the entire genome of individualized breast cancers to help personalize cancer at the 2012 ESMO Congress. They found that this approach is feasible and enables identification of genetic alterations that can be targeted by available drugs. They also saw early signs of [ Read More ]

Phoebe Starr

2012 ESMO Congress

Cultivating Personalized Medicine Clinical Acumen in the Management of Breast Cancer:

An Interview with Edith Perez, MD

If any cancer can be said to have launched personalized medicine into orbit and establish it as the standard for all cancer therapy to aspire toward, it is breast cancer. The discovery of the estrogen receptor (ER) and HER2 biomarkers has astonished healthcare professionals and the public alike and raised [ Read More ]

Edith Perez, MD

Interview with the Innovators

The Role of Personalized Therapy in the Management of Multiple Myeloma: Case Study of a Patient With a Cytogenetic Abnormality

At the 2012 conference of the Global Biomarkers Consortium, which took place March 9-11, 2012, in Orlando, Florida, Sagar Lonial, MD, from the Winship Cancer Institute and Emory University in Atlanta, Georgia, discussed the use of personalized therapy in the management of multiple myeloma. Case A 55-year-old woman presents with [ Read More ]

Sagar Lonial, MD

Multiple Myeloma

The Cancer Immunotherapy Trials Network: A National Strategy for the Development and Implementation of Immunotherapy for the Treatment of Cancer

Key Points The clinical development of immunotherapy has lagged behind the theoretical and preclinical models, but the potential for durable therapeutic responses has been recognized for many years The lack of widespread clinical expertise with immunotherapy presents a challenge for fully realizing the therapeutic opportunities of emerging immunotherapeutic strategies The [ Read More ]

Howard L. Kaufman, MD, FACS

Immunotherapy

A Personal Introduction and Invitation to Join My Journey Through the World of Personalized Medicine

Welcome to our new column, The Last Word. At the outset, let me comment on the irony of the title, for this is not a forum that presumes to have the “last word” on any aspects of personalized medicine. The column will serve as the concluding editorial in each issue [ Read More ]

Robert E. Henry

The Last Word